AstraZeneca’s COVID-19 vaccine still has market potential despite an expected global oversupply of shots and delays in the vaccine’s approval in the United States, the company’s chief executive Pascal Soriot said on April 29.
GSK’s strong Q1 driven by COVID-19, returning demand for shingles vaccine
Antibodies, Business, Business Intelligence, Consumer Health Care, Consumer Healthcare, Coronavirus Disease 2019 (COVID-19), Earnings per share (EPS), Financials, GlaxoSmithKline, Guidance, Leadership, Operations, Presentations, Quarterly results, Sales, Sales, Sales & Marketing, Sales Guidance, Shingles, Strikes, Therapeutics, VaccinesGlaxoSmithKline exceeded expectations for the company’s first-quarter 2022 sales and earnings forecasts. This was largely driven by GSK’s sales of Xevudy, an antibody treatment against COVID-19 it developed with Vir Biotechnology, and the company’s Shingrix vaccine against shingles.
Johnson & Johnson rescinded the company’s forecast for sales of its COVID-19 vaccine, as hesitancy in low income countries has led to a glut of supply of a shot once hoped to be the inoculation of choice for the developing world.
Vertex Pharmaceuticals Inc. priced the company’s FDA-approved Trikafta, a three-drug combination for cystic fibrosis, at $311,503 per year.
Amarin Corp. provided an update, noting that the company is increasing revenue guidance for 2019 and is planning to expand the sales force for Vascepa due to faster-than-expected growth.